WCM Investment Management LLC Buys 12,060 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

WCM Investment Management LLC grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 110.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,977 shares of the biotechnology company's stock after acquiring an additional 12,060 shares during the quarter. WCM Investment Management LLC's holdings in Sarepta Therapeutics were worth $2,785,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Sarepta Therapeutics by 13.5% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,930 shares of the biotechnology company's stock worth $235,000 after acquiring an additional 230 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Sarepta Therapeutics by 9.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,570 shares of the biotechnology company's stock worth $797,000 after acquiring an additional 568 shares in the last quarter. Yorktown Management & Research Co Inc bought a new position in shares of Sarepta Therapeutics during the fourth quarter valued at $559,000. Retirement Systems of Alabama lifted its holdings in shares of Sarepta Therapeutics by 0.3% during the fourth quarter. Retirement Systems of Alabama now owns 116,145 shares of the biotechnology company's stock valued at $14,122,000 after purchasing an additional 299 shares in the last quarter. Finally, abrdn plc lifted its holdings in shares of Sarepta Therapeutics by 6.2% during the fourth quarter. abrdn plc now owns 457,695 shares of the biotechnology company's stock valued at $55,294,000 after purchasing an additional 26,597 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SRPT has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a report on Thursday. Robert W. Baird lowered their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. StockNews.com downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft initiated coverage on Sarepta Therapeutics in a report on Tuesday. They set a "hold" rating and a $136.00 price target on the stock. Finally, Cantor Fitzgerald raised Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and upped their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of "Moderate Buy" and an average price target of $176.77.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded down $1.51 during trading on Friday, hitting $107.95. 630,697 shares of the company's stock were exchanged, compared to its average volume of 800,737. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 52-week low of $102.15 and a 52-week high of $173.25. The business's 50-day simple moving average is $119.42 and its 200 day simple moving average is $124.85. The company has a market cap of $10.31 billion, a price-to-earnings ratio of 86.36 and a beta of 0.75.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company's stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.